文献速递胸部肿瘤

奥希替尼联合立体定向放疗对比单药治疗EGFR突变肺癌脑转移的随机试验联合分析

Osimertinib and Stereotactic Radiosurgery for Brain Metastases in EGFR-Mutated Lung Cancer: The STARLET Joint Analysis of OUTRUN and LUOSICNS Randomized Trials.
PubMed 文献 · J Thorac Oncol · 2026-01-12

OUTRUN与LUOSICNS两项II期随机试验前瞻性联合分析,比较奥希替尼联合立体定向放疗(SRS)与奥希替尼单药治疗EGFR突变NSCLC脑转移(≤10个可SRS病灶)。79例随机,中位随访39.0个月,12个月颅内无进展生存率差异无统计学意义(11%,95%CI -10%至32%,P=0.31)。联合SRS未显著改善12个月ic-PFS,为首个支持奥希替尼单药用于低负荷脑转移的随机证据。

要点

  • 联合SRS未显著改善12个月颅内无进展生存率(差异11%,P=0.31)
  • 中位颅内PFS联合组21.9个月 vs 单药组17.2个月
  • 联合组3/4级放射性坏死发生率为5%

核心结论

  • 在EGFR突变NSCLC脑转移患者中,奥希替尼基础上联合 upfront SRS 未显著改善12个月颅内无进展生存率。
  • 该联合分析为首个随机证据,支持奥希替尼单药作为低负荷、轻症状脑转移患者的 upfront 治疗。

研究设计与样本

  • 研究类型:两项随机II期试验(OUTRUN和LUOSICNS)的前瞻性联合分析。
  • 入组人群:EGFR突变NSCLC伴脑转移,脑转移病灶≤10个且适合SRS。
  • 随机分组:1:1随机至SRS后奥希替尼(80mg每日)或奥希替尼单药。
  • 样本量:共79例参与者随机(SRS联合组n=39,奥希替尼单药组n=40)。
  • 主要终点:12个月颅内无进展生存率(ic-PFS)。

主要发现

  • 中位随访39.0个月,12个月ic-PFS联合组与单药组差异无统计学意义(11%,95%CI -10%至32%,P=0.31)。
  • 中位ic-PFS联合组为21.9个月,单药组为17.2个月。
  • 中位总生存期联合组为46.1个月,单药组为29.1个月。
  • 颅内进展后接受SRS的比例:联合组35%,单药组57%。
  • 联合组3/4级放射性坏死发生率为5%。

关键数值与推荐

  • 12个月ic-PFS差异为11%(95%CI -10%至32%,P=0.31),无统计学显著性。
  • 中位ic-PFS:联合组21.9个月 vs 单药组17.2个月。
  • 中位OS:联合组46.1个月 vs 单药组29.1个月。
  • 3/4级放射性坏死发生率:联合组5%。

临床怎么用

  • 对于EGFR突变NSCLC伴低负荷、轻症状脑转移患者,可考虑奥希替尼单药作为upfront治疗,无需常规联合SRS。
  • 联合SRS时需警惕3/4级放射性坏死风险(5%)。
  • 颅内进展后仍可进行SRS salvage,单药组57%接受了进展后SRS。

局限性

  • 两项II期试验的联合分析,样本量较小(共79例)。
  • 原文未报告总生存期差异的统计学检验结果。
  • 随访时间及入组人群限于低负荷脑转移(≤10个病灶),外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Clinical guidelines recommend upfront osimertinib monotherapy for asymptomatic brain metastases (BM) in EGFR-mutant NSCLC, despite a lack of randomized trial evidence. We conducted two randomized phase II trials, OUTRUN and LUOSICNS, to evaluate the efficacy and safety of upfront stereotactic radiosurgery (SRS) plus osimertinib versus osimertinib in this patient population. METHODS: Participants with up to ten BM amenable to SRS were randomized 1:1 to SRS followed by osimertinib (80 mg daily) or osimertinib monotherapy. SRS was delivered as a single or multi-fraction regimen. The primary end point was 12-month intracranial progression-free survival (ic-PFS). Key secondary end points include overall survival (OS), patterns of intracranial progression, and safety. Data from both trials were prospectively pooled for a joint analysis. RESULTS: Overall, 79 participants were randomized. At a median follow-up of 39.0 months, 12-month ic-PFS was not significantly different between SRS plus osimertinib (n = 39) than osimertinib monotherapy (n = 40) (11%, 95% CI: -10% to 32%, p = 0.31; median ic-PFS 21.9 mo versus 17.2 mo). Median OS was 46.1 versus 29.1 months. Among those with intracranial progression, 35% in the SRS plus osimertinib group and 57% in the osimertinib monotherapy group underwent SRS at progression. Grade 3/4 radionecrosis occurred in 5% of participants treated with SRS plus osimertinib. CONCLUSIONS: Adding upfront SRS to osimertinib did not significantly improve 12-month ic-PFS in EGFR-mutant NSCLC with BM. This represents the first randomized evidence supporting the use of osimertinib monotherapy as upfront therapy in minimally symptomatic patients with low-burden BM. GOV IDENTIFIER: OUTRUN: NCT03497767; LUOSICNS: NCT03769103.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Lee CK, Lefresne S, Soon YY, et al. Osimertinib and Stereotactic Radiosurgery for Brain Metastases in EGFR-Mutated Lung Cancer: The STARLET Joint Analysis of OUTRUN and LUOSICNS Randomized Trials. J Thorac Oncol. 2026. PMID: 41534788. doi:10.1016/j.jtho.2026.01.001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。